Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559943 | 0.86 | NPC1 (0.75) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL104337 | 0.86 | RAB9A (0.75) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1575190 | 0.85 | NPC1 (0.74) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL104605 | 0.83 | NPC1 (0.71) | RAB9ANPC1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL6764523 | 0.83 | NPC1 (0.71) | RAB9ANPC1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL178526 | 0.83 | NPC1 (0.71) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL5852053 | 0.83 | GAA (0.73) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL10594359 | 0.83 | GAA (0.73) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL2475796 | 0.83 | GAA (0.73) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL8312462 | 0.83 | GAA (0.73) | RAB9ANPC1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | RAB9A 3030/4885NPC1 1892/4885MEN1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.